ArticleNature communications2022
Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
Open access · greenAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 60 citations in OpenAlex.
- Recent Advances in the Design of Inhibitors Targeting the Viral Entry and Replication of the SARS-CoV-2 Virus, Driven by In Silico Approaches.Molecules (Basel, Switzerland) · 2026Review
- Design, synthesis, and X-ray structural studies of potent SARS-CoV-2 Mpro inhibitors containing tetrahydroisoquinoline-3-carboxamides as P2 ligands.RSC medicinal chemistry · 2026Article
- Drug Repurposing as a Broad-Spectrum Strategy Against Coronaviruses: Frontiers in Mechanisms and Clinical Translation.Viruses · 2026Review
- Decoding Enzyme-Inhibitor Kinetic Mechanisms by Isothermal Titration Calorimetry: The Case of SARS-CoV-2 3CLAnalytical chemistry · 2026Article
- Structural insights into RNase H catalytic mechanism from room-temperature X-ray and neutron crystallography of apo- and RNA/DNA hybrid-bound enzyme.Current research in structural biology · 2026Article
- Cleavage at the nsp5-nsp6 site of SARS-CoV-2 main protease intermediate precursor is faster from a monomer than a dimer form.The Journal of biological chemistry · 2026Article
- Interaction-constrained 3D molecular generation using a diffusion model enables structure-based pharmacophore modeling for drug design.npj drug discovery · 2026Article
- Characterization of the Cross-Resistance of SARS-CoV‑2 Main Protease Inhibitors, Ibuzatrelvir, Ensitrelvir, and Nirmatrelvir.ACS pharmacology & translational science · 2026Article
- Design and In Vitro Evaluation of Novel GC373-like SARS-CoV-2 Main Protease Inhibitors.Current issues in molecular biology · 2026Article
- Artificial Intelligence in Computer-Aided Drug Design (CADD) Tools for the Finding of Potent Biologically Active Small Molecules: Traditional to Modern Approach.Combinatorial chemistry & high throughput screening · 2026Review
- Article
- Prospects for the structure‒function evolution of SARS-CoV-2 main protease inhibitors.Journal of computer-aided molecular design · 2025Review
- Characterization of an unusual SARS-CoV-2 main protease natural variant exhibiting resistance to nirmatrelvir and ensitrelvir.Communications biology · 2025Article
- Prediction of enzyme inhibition (ICJournal of molecular modeling · 2025Article
- Article
- Identification of potential COVID-19 Mpro inhibitors through covalent drug docking, molecular dynamics simulation, and MMGBSA calculation.Scientific reports · 2025Article
- Current and future perspectives for structural biology at the Grenoble EPN campus: a comprehensive overview.Journal of synchrotron radiation · 2025Review
- Study of Cytotoxicity of 3-Azabicyclo[3.1.0]hexanes and Cyclopropa[International journal of molecular sciences · 2025Article
- The Dynamical Asymmetry in SARS-CoV2 Protease Reveals the Exchange Between Catalytic Activity and Stability in Homodimers.Molecules (Basel, Switzerland) · 2025Article
- Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds.International journal of molecular sciences · 2025Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
14 authors at 5 institutions in 2 countries.
Daniel W KnellerNeutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA.
Hui LiCenter for Nanophase Materials Sciences, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA.
Gwyndalyn PhillipsNeutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA.ORCID 0000-0001-5858-3825
Kevin L WeissNeutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA.ORCID 0000-0002-6486-8007
Qiu ZhangNeutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA.
Mark A ArnouldCenter for Nanophase Materials Sciences, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA.ORCID 0000-0003-0172-8311
Colleen B JonssonDepartment of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, 38103, USA.
Surekha SurendranathanRegional Biocontainment Laboratory, The University of Tennessee Health Science Center, Memphis, TN, 38105, USA.
Jyothi ParvathareddyRegional Biocontainment Laboratory, The University of Tennessee Health Science Center, Memphis, TN, 38105, USA.
Matthew P BlakeleyLarge Scale Structures Group, Institut Laue-Langevin, 71 Avenue des Martyrs, 38000, Grenoble, France.ORCID 0000-0002-6412-4358
Leighton CoatesSecond Target Station, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA.ORCID 0000-0003-2342-049X
John M LouisLaboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD, 20892-0520, USA.ORCID 0000-0002-0052-1899
Peter V BonnesenCenter for Nanophase Materials Sciences, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA. bonnesenpv@ornl.gov.ORCID 0000-0002-1397-8281
Andrey KovalevskyNeutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA. kovalevskyay@ornl.gov.ORCID 0000-0003-4459-9142
Oak Ridge National Laboratory · USUniversity of Tennessee Health Science Center · USInstitut Laue-Langevin · FRNational Institute of Diabetes and Digestive and Kidney Diseases · USTarget (United States) · US
Funding
Biochemical and Structural Studies of Viral ProteasesZIADK075166 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LOUIS, JOHN · 2022 to 2025
$3.4MAbstract
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19 vaccines, and small-molecule antivirals can provide an important therapeutic treatment option. The viral main protease (M
Indexed as
COVID-19 Drug TreatmentSARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesCOVID-19 VaccinesCyclopropanesHumansLactamsLeucineNitrilesProlineProtease InhibitorsSulfonesUrea3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesCOVID-19 VaccinesCyclopropanesLactamsLeucineN-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamidenarlaprevirnirmatrelvirNitrilesProlineProtease InhibitorsSulfonesUrea
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.